September 27, 2022 7:49am
Upside futures could set the tone for Tuesday’s sector’s equities
Indications: 3 Negative and 3 Positive Indications with 1 Pump/Promote (BSTG – the usual suspect)
The cell and gene therapy sector shows more signs of downside movement alternating to continued weakness.
No tunnel vision here, this analyst/journalist gets into the weeds of daily share pricing and root causes
8:00 a.m. edition
Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session.
Dow futures are UP +1.04% or (+304 points), S&P futures are UP +1.31% or (+48 points) and NASDAQ futures are UP +1.56% or (176 points) early in the pre-open – so far,
Stock futures rose Tuesday, as indexes try to bounce back,
European markets inched higher,
Asia-Pacific markets were mostly up.
Henry’omics:
Indexes waivered and then fell to the floorboards on Monday, with more volatility in store as fears of Fed tightening and wild run-in currency markets rattle investors.
The Dow closed DOWN -325.91 points (-1.10%) the S&P closed DOWN -37.76 points (-1.02%) while the Nasdaq closed DOWN -65 points (-0.60%)
Economic Data Docket: September consumer confidence, August durable goods orders and July home prices.
RegMed Investors’ (RMi) closing bell: “playing the bounce game after a very brief upside open. Moving into its electronic trading dynamics; buy/bid them up and then sell ‘em down.” … https://www.regmedinvestors.com/articles/12620
Ebb and flow:
Q3/22 – September – 1 holiday, 7 positive and 10 negative closes
• August – 1 neutral, 11 positive and 11 negative closes
• July - 1 holiday, 10 negative and 10 positive closes
Companies in my headlights – It’s your decision; I provide ideas and context: INDICATIONS
Negative Indication:
Ultragenyx (RARE) closed down-$1.54 to $39.96 after Friday’s -$1.64 with a negative -$0.96 or -2.40% pre-open indication,
Beam Therapeutics (BEAM) closed down -$0.53 to $46.56 after Friday’s $1.06, Thursday’s -$3.47, Wednesday’s -$1.86 and last Tuesday’s -$0.31 following the previous Monday’s -$2.33), with a negative -$0.86 or -1.85% pre-open indication,
BioLife Solutions (BLFS) closed down -$0.64 to $21.59 after Friday’s -$0.08 with a negative -$0.59 or -2.73% pre-open indication,
Positive Indications:
Maintaining BUY:
Agenus (AGEN) closed down -$0.17 to $1.96 after Friday’s -$0.11 with a positive +$0.04 or +2.04% pre-open indication,
CRISPR Therapeutics (CRSP) closed down -$2.06 to $61.10 after Friday’s -$1.74, Thursday’s -$1.75, Wednesday’s -$3.48 and last Tuesday’s +$1.31 following the previous Monday’s -$1.71 with a positive +$1.90 or +3.11% pre-open indication,
uniQure NV (QURE) closed down -$0.32 to $16.98 after Friday’s -$0.29 with a positive +$0.17 or +$1% pre-open indication,
Puff/Pump and Promote: Maintaining SELL
Biostage (OTCQB: BSTG) closed up =$0.39 with 970 shares traded after Friday’s -$1.39 with 2,051 shares traded, Thursday’s FLAT again with 1,844 shares traded, Wednesday’s FLAT with 3,196 shares traded and last Tuesday’s +$0.10 with 9,718 shares traded, <3-month average = 2,079>,
Questions need to be answered and they NEVER are for shareholders; as the First Amendment of the U.S. Constitution does guarantee the “freedom of speech, or of the press” … but I guess NOT to respond?
- Who, WHAT and WHERE are pumping and promoting the “spikes” in volume and share price … coming from?
- What is DST Capital? Is DST Capital really managed by Mrs. bin Zhao of Weston, Mass and Hong Yu, president of BSTG? Is LIU Dong-hai chairman of D. Phone, one of the largest smartphone retailers in China and Dixintong Technology group; the ultimate funder of DST Capital?
- Are Chinese communist bureaucrats from Beijing, China directing the company’s activities with BSTG being their corporate “concubine”?
The BOTTOM LINE: after a tough week and a very week Monday, SOME upside is due for SOME cell and gene therapy sector equities.
Problem, another quarter (Q3) about to close … and then back to earnings season – that’s LPS (loss-per-share) period!
I try to keep it simple … and short as I love my coverage list – yet, the truth will set investors free from electronic and algorithm control!
As I continually write, “The real question that should be asked is how many companies are at the end of sentiments … leash? Start by looking at cell and gene therapy companies trading below cash!”
When it comes time to invest or even hold onto an investment; I’d say … focus on what percentage ownership of stock … NOT options CEOs and management teams own versus their salary and bonus.
As I have written, “I devote a lot of time to the direction of the sector to reckon the geography of my coverage group.”
That doesn't mean you should flee entirely to cash, but investors make sure gains don't evaporate thus … be quick to drop losing positions.
Whether information or intelligence is good, bad or somewhere in between; RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
All investments are subject to risks. Investors should consider investment objectives.
Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions securities referred to in this publication.
